BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30784017)

  • 21. Gastric mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) with pancreatic acinar differentiation: a case report.
    Fujita Y; Uesugi N; Sugimoto R; Eizuka M; Matsumoto T; Sugai T
    Diagn Pathol; 2019 May; 14(1):38. PubMed ID: 31077220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Outcomes in Patients With Small- and Large-Cell Neuroendocrine Carcinoma (NEC) and Mixed Neuroendocrine-Non-Neuroendocrine Neoplasm (MiNEN) of the Stomach.
    Choi NY; Kim BS; Oh ST; Yook JH; Kim BS
    Am Surg; 2021 Apr; 87(4):631-637. PubMed ID: 33142079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mixed neuroendocrine-nonneuroendocrine neoplasms of the gastrointestinal system: An update.
    Elpek GO
    World J Gastroenterol; 2022 Feb; 28(8):794-810. PubMed ID: 35317101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroendocrine neoplasms of liver - A 5-year retrospective clinico-pathological study applying World Health Organization 2010 classification.
    Burad DK; Kodiatte TA; Rajeeb SM; Goel A; Eapen CE; Ramakrishna B
    World J Gastroenterol; 2016 Oct; 22(40):8956-8966. PubMed ID: 27833387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rectal mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN): High grade evolution of a MANET?
    Grillo F; Valle L; Sammito G; Scabini S; Albertelli M; Mastracci L
    Pathol Res Pract; 2020 Apr; 216(4):152869. PubMed ID: 32089407
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-term survival of gastric mixed neuroendocrine-non-neuroendocrine neoplasm: Two case reports.
    Woo LT; Ding YF; Mao CY; Qian J; Zhang XM; Xu N
    World J Clin Cases; 2022 Aug; 10(22):7936-7943. PubMed ID: 36158478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) of pancreas: a rare entity-worth to note.
    Varshney B; Bharti JN; Varshney VK; Yadav T
    BMJ Case Rep; 2020 Apr; 13(4):. PubMed ID: 32345587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroendocrine neoplasms of the gallbladder: A single institute analysis of outcomes and prognostic factors.
    Nandy K; Patkar S; Yadav S; Ostwal V; Ramaswamy A; Bhargav P; Goel M
    J Surg Oncol; 2024 May; 129(6):1121-1130. PubMed ID: 38348696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinicopathological spectrum of olfactory neuroblastoma and sinonasal neuroendocrine neoplasms: Refinements in diagnostic criteria and impact of multimodal treatments on survival.
    Turri-Zanoni M; Maragliano R; Battaglia P; Giovannardi M; Antognoni P; Lombardi D; Morassi ML; Pasquini E; Tarchini P; Asioli S; Foschini MP; Sessa F; Nicolai P; Castelnuovo P; La Rosa S
    Oral Oncol; 2017 Nov; 74():21-29. PubMed ID: 29103747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of Areas for Improvement in the Management of Bone Metastases in Patients with Neuroendocrine Neoplasms.
    Lim KHJ; Raja H; D'Arienzo P; Barriuso J; McNamara MG; Hubner RA; Mansoor W; Valle JW; Lamarca A
    Neuroendocrinology; 2020; 110(7-8):688-696. PubMed ID: 31639796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms.
    Borghesani M; Reni A; Lauricella E; Rossi A; Moscarda V; Trevisani E; Torresan I; Al-Toubah T; Filoni E; Luchini C; De Robertis R; Landoni L; Scarpa A; Porta C; Milella M; Strosberg J; Cives M; Cingarlini S
    J Natl Compr Canc Netw; 2024 May; ():1-8. PubMed ID: 38744314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine/Non-neuroendocrine Neoplasms.
    La Rosa S
    Endocr Pathol; 2021 Jun; 32(2):245-257. PubMed ID: 33786701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms.
    Chatzellis E; Angelousi A; Daskalakis K; Tsoli M; Alexandraki KI; Wachuła E; Meirovitz A; Maimon O; Grozinsky-Glasberg S; Gross D; Kos-Kudła B; Koumarianou A; Kaltsas G
    Neuroendocrinology; 2019; 109(4):333-345. PubMed ID: 31167197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mixed neuroendocrine nonneuroendocrine neoplasms of the pancreas: a case report and literature review of pancreatic mixed neuroendocrine nonneuroendocrine neoplasm.
    Wang F; Lou X; Qin Y; Xu X; Yu X; Huang D; Ji S
    Gland Surg; 2021 Dec; 10(12):3443-3452. PubMed ID: 35070904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
    Kaltsas GA; Mukherjee JJ; Isidori A; Kola B; Plowman PN; Monson JP; Grossman AB; Besser GM
    Clin Endocrinol (Oxf); 2002 Aug; 57(2):169-83. PubMed ID: 12153595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms of the Pancreas.
    Tsvetkova V; Luchini C
    Surg Pathol Clin; 2022 Sep; 15(3):555-563. PubMed ID: 36049836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
    Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
    JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mixed neuroendocrine-non-neuroendocrine neoplasms of the right colon: a case report.
    Barkaoui ZE; Najih M; Mehdi AE; Majdoubi HE; Messaoudi IE; Essaoudi MA; Bouzroud M; Bouchentouf SM; Kaoui HE; Bounaim A
    Pan Afr Med J; 2021; 40():243. PubMed ID: 35233263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinicopathological features of colorectal neuroendocrine neoplasms and prognostic significance of WHO staging system].
    Zhang XH; Lu XL; Wu N; Liu B; Wang FY; Zhang RS; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):191-6. PubMed ID: 23769440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
    Thakral P; Sen I; Pant V; Gupta SK; Dureja S; Kumari J; Kumar S; Un P; Malasani V
    Br J Radiol; 2018 Nov; 91(1091):20170172. PubMed ID: 30028180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.